Dr. Teichner's Curriculum Vitae

Map / Directions to Our Clinic Neuropsychological Assessment Dr. Teichner's Research Publications and Presentations Forensic  Neuropsychological and Psychological Assessment Dr. Teichner's Curriculum Vitae Learning Disabilities and ADHD Helpful Links Home Page Gordon Teichner, Ph.D., ABPP Pediatric Neuropsychological Assessment Scheduling Appointments Join Our Team!

CURRICULUM VITAE - Gordon Teichner, Ph.D., ABPP

SUMMARY: I am a Licensed Clinical Psychologist in the state of South Carolina. I am Board Certified in Clinical Psychology per the American Board of Professional Psychology. I am also a Fellow of the American Academy of Clinical Psychology. I obtained a Ph.D. in Clinical Psychology, with a specialty in Neuropsychology, from Nova Southeastern University. I completed my Clinical Psychology Internship, which included a 50% Neuropsychology emphasis, at the Medical University of South Carolina / Ralph H. Johnson Department of Veterans Affairs Medical Center Consortium in Charleston, South Carolina. I then completed a two-year Neuropsychology Fellowship at the Medical University of South Carolina. I am a Neuropsychologist / Clinical Psychologist with an Independent Private Practice that is located in Mt. Pleasant, South Carolina. I am concurrently actively involved in a number of clinical research studies. My speciality areas include: Neuropsychological Assessment (e.g., children; adolescents; adults; geriatric; traumatic brain injury; closed head injury; dementia; Alzheimer's Disease; stroke), Forensic Assessment / Consultation (e.g., injury litigation, disability, workers compensation, fitness-for duty, Independent Medical Exam, competency, criminal responsibility, fitness to parent, court ordered psychological exam), Psychological Assessment (e.g., ADHD, Learning Disorders, personality assessment, diagnostic clarification), and Psychological Treatment (e.g., depression, anxiety disorders). I have been a Sub-Investigator on 24 Clinical Research Studies to date examining the efficacy of medications for ADHD, childhood Anxiety Disorders, Tourette's Disorder, Binge Eating Disorder, Depression, and Smoking Cessation. At present, I have authored or co-authored 26 scientific articles in peer-reviewed journals, 23 journal abstracts, and have given 80+ presentations (posters, papers, and symposia) at national and state conferences including the National Academy of Neuropsychology, International Neuropsychological Society, American Psychological Association, and the American Academy of Behavior Therapy. I hold membership in the National Academy of Neuropsychology, American Psychological Association, American Psychological Association Division 40 (Neuropsychology), South Carolina Psychological Association, American Board of Professional Psychology, and American Academy of Clinical Psychology.

EDUCATION / CERTIFICATION:

Board Certified in Clinical Psychology (#6194) - July, 2006, American Board of Professional Psychology.

Licensed Clinical Psychologist (SC#800) - November, 2000 - present, South Carolina Board of Examiners in Psychology.

Fellowship in Clinical Neuropsychology - July 2000 - August, 2001, Department of Neurology; Medical University of South Carolina, Charleston, S.C.

Fellowship in Clinical Neuropsychology - August, 1999 - July, 2000, Department of Psychiatry & Behavioral Sciences, Medical University of South Carolina, Charleston, S.C.

Clinical Psychology Internship, -1998-1999, Medical University of South Carolina / Ralph H. Johnson Department of Veterans Affairs Medical Center Consortium, Charleston, S.C.

PhD (Clinical Psychology / Neuropsychology) 1994-1999; Nova Southeastern University, Ft. Lauderdale, Florida.

Masters of Science (Clinical Psychology) - 1995, Nova Southeastern University, Ft. Lauderdale, Florida.

Bachelor of Arts (Honors) in Psychology - 1992, Simon Fraser University, Vancouver, Canada.

Associate of Arts Diploma - 1988, Douglas College, New Westminster, B.C., Canada.

CLINICAL and RESEARCH POSITIONS:

Private Practice (August, 2001 - present).

Research Consultant / Sub-Investigator - Coastal Carolina Research Center, Mount Pleasant, SC (Nov., 2011 - present).

Neuropsychology / Clinical Psychology Consultant - Ralph H. Johnson Veterans Administration Medical Center; Police Services (Fitness for Duty Evaluations for all Police Officers); Occupational Health (Fitness for Duty Evaluations for VA employees), Neuropsychological Assessment / Consultation, (2008-present).

Neuropsychology / Clinical Psychology Consultant - Palmetto Lowcountry Behavioral Health (2005-2010).

Neuropsychology / Clinical Psychology Consultant - Strand Regional Speciality Associates, Myrtle Beach, SC (2001-2005).

Clinical Assistant Professor, Medical University of South Carolina (MUSC), Department of Pediatrics (April, 2002 - July, 2004); Clinical Assistant Professor, MUSC, Dept. Neurology (April, 2002-December, 2004).

Private Practice, Edgewater Psychiatry (July, 2000 - August, 2001).

Post-Doctoral Fellow in Neuropsychology, (Aug., 1999 to Aug., 2001).  Medical University of South Carolina .

Clinical Psychology Intern - Medical University of South Carolina / Ralph H. Johnson Department of Veterans Affairs Medical Center Consortium (Aug., 98 to Aug., 99) - Neuropsychology Track.

Program Coordinator / Clinician (Clinical Psychology / Neuropsychology) - Nova Southeastern University Youth Center (Sept. 96 to Aug., 98).

Clinician (Clinical Psychology) - Nova Southeastern University Center for Older Adults (Practicum: June 96 - May 97).

Clinician (Clinical Psychology / Neuropsychology) - Nova Southeastern University Brain Injury Rehabilitation Program (Practicum: May 95 - April 96).

Behavior Therapist/Clinician (Clinical Psychology / Neuropsychology) - A & B Psychology Clinic, Ft. Lauderdale, FL. (March 95-July, 98).

Clinician (Clinical Psychology) - Nova Southeastern University Interpersonal Violence Program (March 95 - Sept. 95).

Research Assistant/Therapist - Nathan H. Azrin, Ph.D. (Research Practicum: May 95 - Sept.96).

Research Assistant / Neuropsychological Psychometrician - Charles Golden, Ph.D., Vincent B. Van Hasselt, Ph.D. (Aug.94 - Aug. 95).

Research Assistant - Charles Golden, Ph.D. (Aug. 94 - Aug. 98).

Case Manager - Nova Southeastern University Medical Management Program (Jan. 95 - Sept. 95).

Case Manager - Nova Southeastern University Community Support Program (Pre-Practicum: Aug. 94 - May 95).

Residential Supervisor (July, 1992 - Aug., 1994), Child Care Worker (1989 - 1991), Proactive Community Services Society, Richmond, B.C., Canada.

Laboratory Supervisor (1990-1993), Teaching Assistant (1991-1992), Research Assistant (1989-1992), Psychology Department, Simon Fraser University, Burnaby, B.C., Canada.

Consultant / Research Associate (1990 - April, 1993; contract work) - B.C. Council for the Family, #204 - 2590 Granville Street, Vancouver, B.C., Canada.

Research Assistant (Jan. -Aug., 1991), Willingdon Youth Detention Centre, Burnaby, B.C., Canada.

Crisis Intervention Counselor (1988-90), "Lifeline" Crisis and Information Centre, Coquitlam, B.C., Canada.

Daycare counselor (Sept-Dec., 1989; Practicum) - Simon Fraser University Daycare.

CLINICAL RESEARCH STUDIES:

2012 Sub-Investigator, A Phase 4, Randomized, Double-Blind, Active and Placebo-Controlled, Multicenter Study evaluating the Neuropsychiatric Safety and Efficacy of 12 weeks Varenicline tartrate 1 mg BID and Buproprion hydrochloride 150 mg BID for Smoking Cessation in Subjects with and without a history of Psychiatric Disorders.

2012 Sub- Investigator, A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years with Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).

2012 Sub-Investigator, The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years with Moderate to Severe Binge Eating Disorder.

2012 Sub-Investigator, A Phase 3, Multicenter, Open-label, 12-month Extension Safety and Tolerability Study of SPD489 in the Treatment of Adults with Binge Eating Disorder.

2013 Sub-Investigator, A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents with Tourette's Disorder.

2013 Sub-Investigator, An Open-Label, Multicenter Study Evaluating the Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents with Tourette's Disorder.

2013 Sub-Investigator, A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Dose-optimization Safety and Efficacy Study of SPD490 (Vyvanse) Compared with OROS-MPH (Concerta) with a Placebo Arm, in Adolescents Aged 13-17 Years with Attention Deficit / Hyperactivity Disorder (ADHD).

2014 Sub-Investigator, A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 with Moderate to Severe Binge Eating.

2014 Sub-Investigator, A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP-225289 in Adults with Attention Deficit Hyperactivity Disorder (ADHD).

2014 Sub-Investigator, Phase 3, A Randomized, Double-Blind, Multicenter, Placebo-controlled, Parallel-group, Efficacy and Safety Study of 2 Doses of Dasotraline in Adults with Attention Deficit Hyperactivity Disorder (ADHD).

2014 Sub-Investigator, A Randomized, Double-Blind, Placebo-Controlled, Phase 4, Relapse Prevention Study Evaluating the Efficacy and Safety of Vortioxetine (5, 10 and 20 mg) in Adults With Major Depressive Disorder.

2015 Sub-Investigator, Phase 3, A Randomized, Double-Blind, Multicenter, Placebo-controlled, Parallel-group, Efficacy and Safety Study of 2 Doses of Dasotraline in Adults with Attention Deficit Hyperactivity Disorder (ADHD).

2015 Sub-Investigator, Phase 3, Randomized, Double-blind, Multi-center, Placebo-controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Ages Aged 6-17 Years with Attention-Deficit Hyperactivity Disorder (ADHD).

2015 Sub-Investigator, Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Forced dose Titration, Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years with Attention-deficit / Hyperactivity Disorder (ADHD).

2016 Sub-Investigator, Phase 2, Evaluation of SPN-812 ER Efficacy and Safety in Children with ADHD – A Double-Blind, Placebo-Controlled, Dose-Ranging Study.

2016 Sub-Investigator, A Noninterventional Genotype/Phenotype Study of mGluR Mutations in Children and Adolescents with Attention Deficit Hyperactivity Disorder (ADHD).

2016 Sub-Investigator, Phase 2, Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of SPN-812 ER for the Treatment of Pediatric Patients with Attention Deficit/Hyperactivity Disorder (ADHD).

2016 Sub-Investigator, Phase 2, A Multicenter, 6-Week, Double-blind, Randomized, Placebo-controlled, Parallel-design Study to Assess the Efficacy and Safety of NFC-1 in Adolescents (Ages 12-17 Years) with Genetic Disorders Impacting Metabotropic Glutamate Receptors and Attention Deficit/Hyperactivity Disorder.

2016 Sub-Investigator, Phase 3, A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder.

2016 Sub-Investigator, Phase 3, A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients with Major Depressive Disorder.

2016 Sub-Investigator, Phase 3, An Open-label, Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients with Major Depressive Disorder.

2017 Sub-Investigator, A Phase 3, Randomized, Double-blind, Multicenter, Parallel-group, Placebo-controlled, Dose-optimization Safety and Efficacy Study of SPD489 Compared with Placebo in Preschool Children Aged 4-5 Years with Attention-Deficit/Hyperactivity Disorder.

2017 Sub-Investigator, A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years Diagnosed with Attention-Deficit/Hyperactivity Disorder.

2017 Sub-Investigator, Phase IIb, A Two-Stage, Multicenter, Double-Blind, Randomized, Parallel Group, Active- and Placebo-controlled, Adaptive Dose Finding Study to Assess the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to an Antidepressant in Adult Subjects with Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy.

JOURNAL EDITORIALS / GRANT REVIEWS:

  • Drug and Alcohol Review (Guest Editor - 2009) 
  • Medical Research Council Grant Review (2006)
  • Journal of Consulting and Clinical Psychology (Guest Editor - 2005)
  • Drug and Alcohol Dependence (Guest Editor - 2005)
  • Psychiatry Research (Guest Editor - 2005)
  • National Institute of Mental Health (Reviewer for B-Start Grant, 2003)
  • Neuropsychology (Guest Editor - 2001)
  • Addictive Behaviors (Guest Editor - 2001)
  • Journal of Developmental Disabilities (Guest Editor - 2000)
  • Aggression and Violent Behavior (Guest Editor - 2000)
  • Journal of Substance Abuse Research (Guest Editor - 1999)
  • Perceptual Organization & Development (Guest Editor - 1999)

MEMBERSHIPS:

  • American Board of Professional Psychology
  • American Academy of Clinical Psychology
  • National Academy of Neuropsychology
  • American Psychological Association
  • American Psychological Association; Div. 40 (Neuropsychology)
  • South Carolina Psychological Association  

PUBLICATIONS and PRESENTATIONS:

See publication listing.

REFERENCES:

Available on request.

 

updated 1/17